Prime Editing Unlocks a Universal Strategy for Restoring Lost Proteins
November 22, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
orap
Synonyms :
Pimozide, pimozide
Class :
Antipsychotic drugs
Brand Name :
orap
Synonyms :
Pimozide, pimozide
Class :
Antipsychotic drugs
Dosage Forms & Strengths
Tablet
1mg
2mg
Dosage Forms & Strengths
Tablet
1mg
2mg
Refer adult dosing
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
It may enhance QTc interval when combined with erythromycin stearate
It may enhance QTc interval when combined with perphenazine
It may enhance the levels when combined with miconazole vaginal by diminishing metabolism
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
when both drugs are combined, there may be an increase in qtc interval
the level of pimozide is increased by lapatinib by decreasing the metabolism
when both drugs are combined, there may be an increase in the QTC interval
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
may increase the CNS depressant effect
may increase the CNS depressant effect
may decrease the therapeutic effect of anti-Parkinson agents
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
CYP3A4 inhibitors increase the concentration of pimozide in the serum
CYP3A4 inhibitors increase the concentration of pimozide in the serum
CYP3A4 inhibitors increase the concentration of pimozide in the serum
CYP3A4 inhibitors increase the concentration of pimozide in the serum
CYP3A4 inhibitors increase the concentration of pimozide in the serum
may enhance the concentration of serum when combined with pimozide
may enhance the concentration of serum when combined with pimozide
may enhance the concentration of serum when combined with pimozide
may enhance the concentration of serum when combined with pimozide
may enhance the concentration of serum when combined with pimozide
May increase the QTc-prolonging effect of QT-prolonging Agents
May increase the QTc-prolonging effect of QT-prolonging Agents
May increase the QTc-prolonging effect of QT-prolonging Agents
May increase the QTc-prolonging effect of QT-prolonging Agents
May increase the QTc-prolonging effect of QT-prolonging Agents
pimozide: they may enhance the serum concentration of CYP3A4 Inhibitors
pimozide: they may enhance the serum concentration of CYP3A4 Inhibitors
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
pimozide: they may enhance the serum concentration of glycoprotein IIa Inhibitors
pimozide: they may enhance the serum concentration of CYP2D6 Inhibitors
pimozide: they may enhance the serum concentration of CYP2D6 Inhibitors
pimozide: they may enhance the serum concentration of CYP2D6 Inhibitors
pimozide: they may enhance the serum concentration of CYP2D6 Inhibitors
pimozide: they may enhance the serum concentration of CYP2D6 Inhibitors
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
QTc interval is increased both by lenvatinib and pimozide
the effect of pimozide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
it increases the effect of the agents which are responsible for QT-prolongation
it increases the QTc prolongation of ondansetron
it increases the QTc-prolonging action of QT-prolonging agents
it increases the effect of QT-prolonging agents
it increases the QTc prolongation of QT-prolonging agents
CYP2C19 Inhibitors increase the concentration of pimozide in serum
it increases the effect of CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the CNS depressing effect of thalidomide
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may have an increasingly adverse effect when combined with antipsychotic agents
may increase the QTc-prolonging effect of QT-prolonging Agents
may enhance the serum concentration of CYP3A4 Inhibitors
may enhance the serum concentration of CYP3A4 Inhibitors
antipsychotic agents increase the effect of arrhythmia of saquinavir
Could potentially reduce the therapeutic efficacy of antipsychotic agents
The potential for increased toxicity of Sulpiride could be amplified by the presence of antipsychotic agents
tiopronin: they may increase the toxic effect of antipsychotic agents
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increasingly adverse effect when combined with amphetamines
may have an increasingly adverse effect when combined with amphetamines
may have an increasingly adverse effect when combined with amphetamines
may have an increasingly adverse effect when combined with amphetamines
may have an increasingly adverse effect when combined with amphetamines
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
it may enhance the CNS depressant effect
it may enhance the CNS depressant effect
it increases the QT-c prolonging effect with gilteritinib
it may increase the neurotoxic effect of antipsychotic agents
It may increase the neurotoxic effect of Antipsychotic Agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
It may increase the neurotoxic effect of Antipsychotic Agents
it may increase the risk of adverse effect of amphetamines
it may increase the risk of adverse effects of antipsychotic agents
it may increase the risk of adverse effects of antipsychotic agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
it may enhance the neurotoxic (central) effect of antipsychotic Agents
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
Serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the sedative effect of CNS depressants
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may increase the hypotensive effect of antihypertensives
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may increase the hypotensive effect of blood pressure-lowering agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the risk of adverse effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increasingly adverse effect when combined with antipsychotic agents
may have an increasingly adverse effect when combined with dexmethylphenidate
may increase the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may have an increased hypotensive effect when combined with antipsychotic agents
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
The Therapeutic efficacy of quinagolide might be reduced
may enhance the QTc-prolonging effect of each other when combined
Could potentially amplify the toxicity of antipsychotic agents
lithium: they may increase the neurotoxic effect of antipsychotic agents
mianserin: they may decrease the therapeutic effect of antipsychotics
may have an increased neurotoxic effect when combined with antipsychotic agents
When pimozide is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
it may increase the effect of CNS depressants
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
it increases the effect of CNS depressants
Mechanism of action
It is an antipsychotic drug that blocks dopamine receptors in the brain. It is primarily used to treat symptoms of schizophrenia and Tourette’s syndrome. The mechanism of action of pimozide is thought to involve the inhibition of dopamine receptors in the brain, which leads to a reduction in the symptoms of psychosis and tics associated with Tourette’s syndrome.
Spectrum
The drug has a relatively narrow spectrum of activity and is not typically used to treat other psychiatric conditions.
Frequency defined:
>10%
Drowsiness
Sedation
Visual disturbance
Constipation
Akinesia
EPS
Speech disorder
Dry mouth
impotence
1-10%
Increased thirst
Dystonia
Photosensitivity
Orthostatic hypotension
Nasal congestion
Urinary retention
Appetite increased
Dizziness
Nervousness
Taste change
Diminished sweating
Diarrhea
Retinitis pigmentosa
Frequency undefined
Heatstroke
Seizures
Paralytic ileus
Disorder of hematopoietic structure
Thrombocytopenia
Death
Ineffective thermoregulation
Neuroleptic malignant syndrome
Prolonged QT interval
Obstipation
Agranulocytosis
Black box warning
The use of pimozide is contraindicated in patients with a history of QT prolongation or with certain heart conditions. Additionally, the drug should be used with caution in patients with a family history of QT prolongation or other risk factors for torsades de pointes. The dose should be limited to the lowest effective dose.
Contraindications
Caution
Pregnancy consideration: C
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology
Pharmacodynamics
Pharmacokinetics
Absorption
The bioavailability of pimozide is approximately 85%. The elimination half-life of pimozide is approximately 20-30 hours
Distribution
It is highly protein bound, with approximately 98% of the drug bound to plasma proteins
Metabolism
It is metabolized primarily by the liver to several active and inactive metabolites
Elimination and excretion
It is excreted primarily in the urine, with a small amount excreted in the feces
Administration
Patient information leaflet
Generic Name: pimozide
Pronounced: [ PIM-oh-zide ]
Why do we use pimozide?
It treats certain mental disorders such as schizophrenia and Tourette’s syndrome.
In treating Tourette’s syndrome: pimozide is used to reduce the frequency and severity of motor and vocal tics. It works by blocking the action of dopamine, a neurotransmitter that is thought to be involved in developing tics. Pimozide is considered a second-line treatment for Tourette’s syndrome and is typically used when other treatments, such as alpha-2 agonists, have been ineffective or poorly tolerated.
In treating schizophrenia: pimozide is used as an adjunct to other antipsychotic medications to treat symptoms such as hallucinations, delusions, and disordered thinking. It works by blocking the action of dopamine and other neurotransmitters in the brain, which can help to reduce the severity of these symptoms
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
